Tint w/ Stationary Glass Door Back LH Van Econoline 1998-2007 NEW YP DB09521 Other Car & Truck Glass


  1. Home
  2. Tint w/ Stationary Glass Door Back LH Van Econoline 1998-2007 NEW YP DB09521
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
1998-2007 Econoline Van LH Back Door Glass Stationary w/ Tint NEW DB09521 YP
Condition: New Brand:

PGW

Manufacturer Part Number:

DB09521 YP

Placement on Vehicle: Left
published on tue nov 09 2021

Tint w/ Stationary Glass Door Back LH Van Econoline 1998-2007 NEW YP DB09521 Other Car & Truck Glass

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Tint w/ Stationary Glass Door Back LH Van Econoline 1998-2007 NEW YP DB09521 Other Car & Truck Glass

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS